Tolmar secures global license to DelSiTech’s Silica Matrix technology to develop and commercialize two undisclosed drug targets
DelSiTech and Tolmar to expand development of additional drug products across a range of therapeutic areas
DelSiTech is eligible to receive upfront payments, development and commercial milestone payments, and royalties on licensed products
TURKU, Finland and DUBLIN, Feb. 13, 2024 /PRNewswire/ — Clinical-stage drug delivery and development company, DelSiTech Ltd., and Tolmar International Ltd., a fully-integrated pharmaceutical company, today announce the signing of a global license and development agreement, further strengthening their collaboration, following investment from Tolmar in January 2024.
Under the terms of the Agreement, Tolmar will obtain a global license to utilize DelSiTech’s proprietary, silica-based, drug delivery technology platform for the development and commercialization of two undisclosed long-acting injectable drug products. In addition, both companies will collaborate to explore additional development opportunities using controlled release drug products based on Silica Matrix across a broad range of therapeutic areas, which include urology, reproductive health, and pediatric …